Intravenous immune globulin for inducing remissions in systemic lupus erythematosus

Annals of Pharmacotherapy

Volumn 31, Issue 2, 1997, Pages 242-244

  Heyneman, Catherine A ^a,c   Gudgtr, Carla A ^b   Deckwlth, Jan V ^b  

^a Idaho Drug Informuiion Center   (United States)

^b IDAHO STATE UNIVERSITY   (United States)

^c Campus Box 8356   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CYTOTOXIC AGENT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; PATIENT SELECTION; PRIORITY JOURNAL; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0031019408     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100218     Document Type: Article

References (27)

1. Kumar V, Cotran RS, Robbins SL. Diseases of immunity. In: Kumar V, Cotran RS, Robbins SL, eds, Robbins pathologic basis of disease. 4th ed. Philadelphia: WB Saunders Co., 1992;193-202.
2. Gladman DD, Urowitz MB. Clinical features. Tn: Schumacher HR, ed. Primer on the rheumatic diseases. 10th ed. Atlanta; Arthritis Foundation, 1993;106-12,
3. Mills JA. Systemic lupus erythematosus. N Engl J Med 1994;330:1871- 9.
4. Spruill WJ, Wade WE. Other connective tissue disorders and the use of glucocorticoids. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics. 5th ed. Vancouver, WA: Applied Therapeutics, Inc., 1992;1-15.
5. Klippel JH. Treatment. In: Schumacher HR, ed. Primer on the rheumatic diseases. 10th ed. Atlanta: Arthritis Foundation, 1993:112-6.
6. Achiron A, Cohen IR, Lider O, Melamed E. Intravenous immunoglobulin treatment in multiple sclerosis. Isr J Med Sci 1995;31:7-9.
7. Silverman ED, Cawkwell GD, Lovell DJ, Laxer RM, Lehman TJ, Passo MH, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis; a randomized placebo controlled trial. J Rheumatol 1994;21:2353-8.
8. Ronda N, Haury M, Nobrega A, Coutinho A, Kazatchkine MD. Selectivity of recognition of variable (V) regions of autoantibodies by intravenous immunoglobulin (IVIG). Clin Immunol Immunopathol 1994; 70:124-8.
9. Gaedicke G, Teller WM, Kohne E, Dopfer R, Niethammer D. IgG therapy in systemic lupus erythematosus - two case reports. Blut 1984;48: 387-90.
10. Winder A, Molad Y, Ostfeld I, Kenet G, Pinkhas J, Sidi Y. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. J Rheumatol 1993;20: 495-8.
11. Francioni C, Galeazzi M, Fioavanti A, Gelli R, Megale F, Marcolongo R. Long term I.V. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994;12:163-8.
12. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum 1982;25:1271-7.
13. Klippel JH. Is aggressive therapy effective for lupus? Rheum Dis Clin North Am 1993;19:249-61.
14. Ochs HD, Buckley RH, Pirofsky B, Fischer SH, Rousell RH, Anderson CJ, et al. Safety and patient acceptability of intravenous immune globulin in 10% maltose. Lancet 1980;2:1158-9.
15. Ben-Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin (letter). N Engl J Med 1992;326:270-1.
16. Frame WD, Crawford RJ. Thrombotic events after intravenous immunoglobulin (letter). Lancet 1986;2:468.
17. Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ. Hemolysis following intravenous immune globulin therapy. Transfusion 1986;26:410-2.
18. Pasatiempo AMG, Kroser JA, Rudnick M, Huffman BI. Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol 1994;21: 347-9.
19. Barton JC, Herrera GA, Galla JH, Bertoli LF, Work J, Koopman WJ. Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. Am J Med 1987;82:624-9.
20. Ellie E, Combe C, Ferrer X. High-dose intravenous immune globulin and acute renal failure. N Engl J Med 1992;327:1032-3.
21. Cantu TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel PJ. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995;25:228-34.
22. Ahsan N, Palmer BF, Wheeler D, Greenlee RG, Toto RD. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med 1994;154: 1985-7.
23. Cantu TG, Hoen-Saric EW, Burgess KM, Racusen L, Scheel PJ. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995;25:228-34.
24. Winward DB, Brophy MT. Acute renal failure after administration of intravenous immunoglobulin: review of the literature and case report. Pharmacotherapy 1995;15:765-72.
25. Schifferli J, Leski M, Fabre H, Imbach P, Nydegger U, Davies K. Highdose intravenous IgG treatment and renal function. Lancet 1991;1:457-8.
26. Ballow M. Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer 1991;68:1430-6.
27. Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989;32:45-53.